...
首页> 外文期刊>Neoplasma: Journal of Experimental and Clinical Oncology >Advanced tracheal carcinoma--a therapeutic significance of HDR brachytherapy in palliative treatment.
【24h】

Advanced tracheal carcinoma--a therapeutic significance of HDR brachytherapy in palliative treatment.

机译:晚期气管癌-HDR近距离放射疗法在姑息治疗中的治疗意义。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The purpose of this study was to determine the benefit of high dose rate endotracheal brachytherapy as an exclusive palliative treatment of obstructive tracheal cancer. Thirty-five patients with advanced tracheal carcinoma were treated between May 1999 and March 2001 in Greatpoland Cancer Center. They were qualified for brachytherapy due to life-threatening situations. Fourteen patients were irradiated using three fractions 7.5 Gy each one every week, six patients received three fractions 10 Gy each one every week and fifteen patients received one fraction of 10 Gy. Survival time was compared with chosen clinical factors (age, sex, Karnofsky status, tumor location, lymph nodes involvement and percent of obturation) and prescribed dose. The median survival (Kaplan-Meier) for all patients was 6.6 months. Patients with an endoscopically controlled complete remission 4 weeks after the treatment had a significantly better survival in comparison to patients with a partial remission or no change of tumor size(p=0.0003). Univariate analysis revealed significant difference between patients with Karnofsky score equal with 60 or lower (28/35, 80%) and higher than 60 (7/35, 20.0%) (p=0.005). Difference between the grade of tumor obturation (more than 60% of tracheal lumen (27/35, 77.1%), 60% or lower (8/35, 22.9%) was found in univariate analysis (p=0.04). In multivariate analysis statistically important prognostic factor for survival was Karnofsky score (p=0.04). Statistical analysis revealed no differences in survival according to sex and age (p=0.43 for age, p=0.19 for sex), tumor localization (p=0.13), lymph node involvement (p=0.48) or fractionation scheme (p=0.62). Exclusive HDR brachytherapy of advanced tracheal carcinoma was a safe palliative method of treatment and caused in many patients prolonged survival and improved quality of life. Most important prognostic factor for survival, confirmed in both univariate and multivariate analysis, was Karnofsky score.
机译:这项研究的目的是确定高剂量率气管内近距离放射疗法作为阻塞性气管癌的唯一姑息治疗的益处。在1999年5月至2001年3月之间,Greatpoland Cancer Center对35例晚期气管癌患者进行了治疗。由于危及生命,他们有资格接受近距离放射治疗。每周接受三部分7.5 Gy的放射线照射14位患者,六名患者每周接受三份10 Gy的放射线照射,十五名患者接受10 Gy的一部分放射线照射。将生存时间与选择的临床因素(年龄,性别,卡诺夫斯基状态,肿瘤位置,淋巴结受累和闭塞百分比)和处方剂量进行比较。所有患者的中位生存期(Kaplan-Meier)为6.6个月。与部分缓解或肿瘤大小无变化的患者相比,治疗后4周内镜控制的完全缓解的患者的生存期明显更好(p = 0.0003)。单因素分析显示Karnofsky评分等于或低于60(28/35,80%)和高于60(7/35,20.0%)的患者之间存在显着差异(p = 0.005)。在单因素分析中发现了肿瘤闭塞程度(气管腔内超过60%(27/35,77.1%),60%或更低(8/35,22.9%)之间的差异(p = 0.04)。生存的统计学上重要的预后因素是Karnofsky评分(p = 0.04),统计分析显示,性别和年龄的生存率无差异(年龄p = 0.43,性别p = 0.19),肿瘤部位(p = 0.13),淋巴结结节受累(p = 0.48)或分级方案(p = 0.62)。晚期气管癌的独家HDR近距离放疗是一种安全的姑息治疗方法,可导致许多患者延长生存期并改善生活质量。最重要的预后因素是在单变量和多变量分析中均得到证实的是卡诺夫斯基评分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号